CSPC Pharmaceutical Group (HK:1093) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CSPC Pharmaceutical Group Limited has announced that its new drug, Omalizumab for Injection (branded as Enyitan®), has received marketing approval from the National Medical Products Administration (NMPA) of China. Enyitan® represents the first biosimilar of Xolair® in China, intended for patients over 12 years old with chronic spontaneous urticaria unresponsive to H1 antihistamine treatments. This approval marks a significant expansion of CSPC’s product line in the autoimmune disease category.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.